How can we recognize "disease modification" effects?
J Nutr Health Aging
.
2009 Apr;13(4):341-3.
doi: 10.1007/s12603-009-0036-7.
Author
E R Siemers
1
Affiliation
1
Alzheimer's Disease Team, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. esiemers@lilly.com
PMID:
19300873
DOI:
10.1007/s12603-009-0036-7
No abstract available
MeSH terms
Alzheimer Disease / diagnosis
Alzheimer Disease / drug therapy*
Alzheimer Disease / physiopathology
Biomarkers / analysis*
Clinical Trials as Topic
Humans
Treatment Outcome
Substances
Biomarkers